San Diego-dependent Viking Therapeutics marked itself as a significant competitor during the weight loss drug industry in February after revealing promising info from a mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when provided for a weekly injection and in March the company unve